Pertuzumab is a novel humanized monoclonal antibody developed for the treatment of HER2 positive breast cancer. It works by selectively blocking the HER2 receptor and inhibiting the HER2-HER3 dimerization, which is the most potent dimer involved in the development of HER2 positive breast cancer. Clinical trials have shown that the combination of Pertuzumab, Trastuzumab and Docetaxel produces higher complete pathological response rates compared to Trastuzumab and Docetaxel alone in the neoadjuvant and metastatic settings. Pertuzumab is the first drug that can block the HER2-HER3 dimerization in addition to Trastuzumab and chemotherapy.

1. Pertuzumab: A novel humanized mAb
for the treatment of HER2 positive
breast cancer.
Prepared by :
Md. Mominul Islam
ID # 162 1405 673
North South University_Mpharm_Summer-17

3. Breast Cancer Facts…
2nd position in case of
cancer deaths.
In every 13 minutes 1
woman will die.

4. Breast Cancer Prevalence in
Bangladesh
Approximately 1.5 lac women
die each year due to cancer
in Bangladesh.
WHO ranked
Bangladesh 2nd
position in mortality
rate of women due
to breast cancer.

5. Types of Breast Cancer

6. HER-2 Positive Breast Cancer

7. HER-2 Positive Breast Cancer
• HER-2 is a protein found on
the surface of normal breast
cells.
• Over expression of these
cells cause HER-2 positive
breast cancer
* HER-2 : Human Epidermal Growth factor receptor-2

8. HER2-HER3 Dimerization
Most potent dimer in the development of HER2 positive breast
cancer

9. Treatment

10. Targeted Therapy-Pertuzumab
The HER2-HER3 dimerization inhibitor.
Pertuzumab gives complementary functions in
combination with Trastuzumab and Docetaxel to
block HER2-HER3 dimerization.

11. Pertuzumab
A novel humanized monoclonal Antibody
It’s development for medical use began in1990
First Marketed as Perjeta by Genetech.

12. Pertuzumab Recommendations

13. Mode of Action

14. Unique Features…
Selectively blocks the HER2 receptor
Only Pertuzumab Inhibits HER2-HER3
dimerization other than Trastuzumab &
Docetaxel.
In combination with Trastuzumab and
Docetaxel, produces better results in
HER2 positive breast cancer
No safety & efficacy limitations observed
with age

15. Why better than existing Drugs?
Conventional treatment of HER2 positive breast cancer
Docetaxel and Trastuzumab blocks HER2-HER2 dimer only,
But
Unable to block the most potent HER2-HER3 dimer.
Where
Pertuzumab can.

16. Pertuzumab VS Trastuzumab with Docetaxel
for neoadjuvant therapy in HER2(+) BC.
Dose:
 Pertuzumab initially 840 mg,
followed by 420 mg for 3 weeks.
 Trastuzumab initially of 8
mg/kg, followed by 6 mg/kg for
3 weeks
 Docetaxel 75-100mg/m2 every
3 weeks
** no. of patients 214
Pertuzumab+Trastuzumab
+Docetaxel
Trsatuzumab+Docetaxel
46%
29%
Complete pathological response in %

17. Pertuzumab VS Trastuzumab with Docetaxel
in metastatic breast cancer.
Dose:
 Pertuzumab initially 840 mg,
followed by 420 mg for 3 weeks.
 Trastuzumab initially of 8 mg/kg,
followed by 6 mg/kg for 3 weeks
 Docetaxel 75-100mg/m2 every 3
weeks
* *No of patients 808

18. Pertuzumab+Gemcitabine Vs Placebo+Gemcitabine in
ovarian cancer treatment
Dose:
 Pertuzumab initially 840 mg,
followed by 420 mg for 3
weeks.
 Gemcitabine 800 mg/m2
for 3 weeks

19. Prescribing Information
Indication:
Metastatic HER2 Breast Cancer, Neoadjuvant Treatment of Breast
Cancer
Dosage and Adminstration:
For intravenous infusion only.
Do not administer as an intravenous push or bolus.
The initial dose is 840 mg as a 60-minute IV infusion, followed every
3 weeks thereafter by 420 mg as a 30 to 60 minute IV infusion.
Precaution:
Special precautions should be taken in patients with cardiac
dysfunctions.

20. Prescribing Information
Pregnancy Category D:
Pertuzumab is contraindicated in pregnancy.
During Lactation:
Breast feeding should be avoided during treatment with Pertuzumab.
Pediatric Use:
Safety and effectiveness of Pertuzumab have not been established in pediatric
patients.
Drug interactions:
Patients who receive anthracycline after receiving Pertuzumab maybe at
increased risk of cardiac dysfunction.
Contraindications:
Pertuzumab is contraindicated in patients with known hypersensitivity to
Pertuzumab or to any of its excipients.